CAS:220991-20-8Lumiracoxib

您的位置 : 首页 / Immunology/Inflammation / COX / Lumiracoxib

Lumiracoxib 罗美昔布 Cat No. FB08388Cas No. 220991-20-8

Synonyms: COX-189

Lumiracoxib is a COX2 selective inhibitor and a non-steroidal anti-inflammatory drug (NSAID), which inhibits COX2 with IC50 and Ki values of 0.14 μM and 0.06 μM and inhibits COX1 with Ki of 3 μM.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.4046 mL
- 17.0230 mL
- 34.0460 mL
- 5 mM
- 0.6809 mL
- 3.4046 mL
- 6.8092 mL
- 10 mM
- 0.3405 mL
- 1.7023 mL
- 3.4046 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

220991-20-8

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C15H13ClFNO2

运输

蓝冰

分子量

293.72

别名

COX-189

溶解度

DMSO	300.0 mg/mL (1021.4 mM)
Water	insoluble

动物实验配方

靶点数据

生物活性

描述Lumiracoxib is a selective cyclooxygenase (COX)-2 inhibitor that possesses a carboxylic acid group that makes it weakly acidic. It has good oral bioavailability; maximum plasma concentrations are reached two hours after oral administration. Lumiracoxib has been found to be effective at doses of 100 - 400 mg once a day for chronic pain and 400 mg/day for acute pain. In comparison to NSAIDs (nonsteroidal anti-inflammatory drugs), patients taking lumiracoxib experience significantly fewer adverse events and greater tolerability^[3]. In single- and multiple-dose well designed trials in patients with acute pain associated with primary dysmenorrhoea, dental or orthopaedic surgery or tension-type headache, lumiracoxib 100 - 800 mg once daily was more effective in relieving acute pain than placebo or controlled-release oxycodone 20 mg, and was at least as effective as selective COX-2 inhibitors or nonselective NSAIDs^[4]. COX-2 selectivity of lumiracoxib is associated with a reduced incidence of gastroduodenal erosions compared with naproxen and a lack of effect on both small and large bowel permeability^[5].